Browse grants

National Institutes of Health · Amount varies

The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

Centers for Disease Control and Prevention - ERA · $0–$150K

This Centers for Disease Control and Prevention (CDC), National Center for Injury Prevention and Control (NCIPC) Mentored Research Scientist Development Award (K01) helps researchers develop skills in violence prevention research. The goal is to support scientists in becoming independent researchers. Applicants must propose a research project that focuses on at least one of the following NCIPC research priorities related to interpersonal violence and suicide affecting children and youth (birth to age 17). These research priorities include adverse childhood experiences, child abuse and neglect, youth violence, intimate partner violence (including teen dating violence), sexual violence, suicide, and cross-cutting preventions (i.e. examining two or more of these priority topics). For more information, see https://www.cdc.gov/injury-violence-prevention/programs/research-priorities.html. Applicants are encouraged to explore multiple forms of interpersonal violence and/or suicide among children or youth, community factors that increase the risk of interpersonal violence and/or suicide, and the practical relevance of the research for prevention and intervention efforts.

Centers for Disease Control and Prevention - ERA · $0–$6M

This notice of funding opportunity (NOFO) supports research, implementation science, and public health evaluations to inform best practices for preventing and responding to infectious disease threats in Kenya, while strengthening local research capacity.The award recipient will conduct research, implementation science, and public health evaluations through the Kenya Medical Research Institute (KEMRI) and focus on four required priority areas:Influenza and other respiratory pathogens: Activities include surveilling high-risk groups; monitoring for human and avian influenza and other pathogens; and evaluating efficacy and use of vaccines and other treatments. Outcomes include increasing understanding of disease burden and improving vaccination strategies.Vaccine-preventable diseases: Research will assess disease burden, vaccine effectiveness, and sociocultural factors influencing immunization. Outcomes include increasing vaccine uptake and strengthening immunization systems.Drug-resistant infections: Activities include monitoring antimicrobial resistance (AMR) trends, applying novel diagnostics, and identifying drivers of resistance. Outcomes include improving mitigation strategies and global AMR preparedness.Global and emerging health threats: Research will address malaria, HIV, tuberculosis, schistosomiasis, and emerging infections. Outcomes include improving understanding of disease dynamics, intervention effectiveness, and cross-border risks.The recipient will also conduct research coordination and administration activities to manage and oversee U.S. government–funded public health research, ensure compliance with financial and ethical standards, and enhance organizational infrastructure. Outcomes include improved management and compliance with federal funding regulations.The proposed activities under this NOFO will generate evidence to guide U.S. and global preparedness, reduce disease burden and health threats in Kenya, and prevent the spread of health threats across borders.

National Institutes of Health · Amount varies

The purpose of this notice of funding opportunity (NOFO) is to support rigorous analytical validation of method(s) used for measuring biomarkers for neurological and neuromuscular disorders for use in clinical trials or clinical practice. Applicants must justify the unmet need for the biomarker(s) and measurement methods and specify one or two context(s) of use for the biomarker(s). Activities supported include optimizing and evaluating the accuracy, precision, reportable range, and analytical sensitivity and specificity of the detection method across multiple sites and operators and establishing reference intervals and quality control procedures. Multi-site applications are expected but not required.

Centers for Disease Control-GHC · $0

The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $3,000,000 for Year 1, subject to the availability of funds.The purpose of this NOFO is to reduce TB-related morbidity and mortality in India, the Philippines, and Vietnam by strengthening:• TB case finding, including linked activities such as screening, testing, and diagnostic evaluation.• TB prevention, including TB preventive treatment (TPT).• TB treatment, including linkage and improved treatment regimens, as appropriate.• Surveillance, through adopting, evaluating, and expanding innovative approaches.Activities implemented will focus on:• Expanding and improving diagnosis of TB infection and TB disease, including early and asymptomatic TB as well as drug-resistant or multidrug-resistant TB. This will be done by using and evaluating innovative screening and diagnostic methods and scaling up evidence-based approaches. • Improving TPT outcomes for all individuals at high risk of developing TB disease and improving TB treatment outcomes of individuals with TB disease, including those with drug-resistant or multidrug-resistant TB. This will be done by using new, shorter, and better-tolerated treatment regimens.• Strengthening TB surveillance for data-driven decision making, program planning, and public health action.Asia carries the highest burden of TB and drug-resistant or multidrug-resistant TB globally. This NOFO will focus on activities in India, the Philippines, and Vietnam because they are three of the top four countries contributing to the TB burden in the U.S. This aligns with the America First Global Health Strategy.

Indian Health Service · $200K–$250K

This program supports Tribes, Tribal organizations, and Urban Indian organizations in implementing produce prescription models that increase access to nutritious and community relevant foods and promote whole-person health and well-being.

Office of National Drug Control Policy · $1–$14M

The Office of National Drug Control Policy (ONDCP), Executive Office of the President, is seeking applications to provide continued support of anti-doping activities to educate athletes on the dangers of drug use and eliminate doping in amateur athletic competitions recognized by the United States Olympic & Paralympic Committee.

National Institutes of Health · Amount varies

The purpose of this proposed Notice of Funding Announcement (NOFO) is to support development of biomarkers or clinical outcomes derived from digital health technology (DHT) for use in clinical trials for remote monitoring as primary or secondary endpoints. To improve clinical impact, increase statistical feasibility, and promote standardization, applicants will be expected to develop and test the digitally derived assessments in populations from at least three different diseases or conditions. Partnerships with non-profit patient advocacy organizations will be required.

Centers for Disease Control and Prevention - ERA · $0–$550K

The National Institute for Occupational Safety and Health (NIOSH) supports research projects that address: (1) physical and mental health conditions related to the September 11, 2001, terrorist attacks; (2) diagnosing conditions for which there has been diagnostic uncertainty; and (3) treating conditions for which there has been treatment uncertainty. Conditions may have emerged since the treatment program began or since the WTC Health Program was established. This announcement solicits meritorious and scientifically rigorous applications that will: 1) improve diagnosis and treatment activities of the WTC Health Program; 2) expand knowledge about health effects related to the September 11, 2001, terrorist attacks; 3) answer critical questions about WTC-related physical and mental health conditions; and 4) apply lessons learned to improve response to future disasters. Potential projects may include, but are not limited to: (a) Screening research to evaluate current methods or facilitate the development of new or improved methods to detect disorders or health conditions; (b) Diagnostic research to evaluate current methods or facilitate the development of new or improved methods to identify diseases, disorders, or conditions; (c) Treatment research to evaluate or identify improved treatment interventions or methods, or to promote development of new or novel approaches; (d) Prevention research to identify or evaluate methods and interventions that prevent or mitigate the development or recurrence of diseases or disorders; (e) Quality of life research to identify, develop, or evaluate methods or interventions that improve comfort and quality of life for individuals with chronic illness or multimorbidity; (f) Omics research to improve methods for predicting disorders by identifying and understanding relationships between genes and illness (e.g., phenotypes and biomarkers), including how genetic factors influence disease development or response to treatment; (g) Epidemiologic or clinical research to identify patterns, causes, and control of adverse health effects among the 9/11-exposed population; (h) Health services research to examine access to care, cost of care, and outcomes associated with care delivery; (i) Implementation research to evaluate how research findings are disseminated, adopted, implemented, sustained, and scaled in real-world settings; and (j) Epidemiologic research to investigate emerging conditions where preliminary data suggest, but do not confirm, a causal relationship between 9/11 exposure and the condition. Examples can be found at https://www.cdc.gov/wtc/received.html.

National Institutes of Health · Up to $200K

Many valuable and widely available data sets have been generated by multiple Common Fund programs. The purpose of this NOFO is to announce the availability of funding to demonstrate and enhance the utility of selected Common Fund (https://commonfund.nih.gov/) data sets, including generating hypotheses and catalyzing discoveries. Award recipients are asked to provide feedback on the utility of the Common Fund data resources.

Centers for Disease Control and Prevention - ERA · $0–$365K

The World Trade Center (WTC) Health Program supports exploratory and developmental research projects (R21) that address issues related to diagnostic or treatment uncertainty among individuals receiving monitoring and/or treatment under Subtitle C of the James Zadroga 9/11 Health and Compensation Act of 2010, as amended. This R21 Notice of Funding Opportunity (NOFO) is intended to encourage exploratory/developmental research by supporting the early and conceptual stages of project development to assess the feasibility of new areas of investigation with the potential to improve treatment effectiveness and diagnostic practices. These studies may lead to breakthroughs in a particular area or to the development of new interventions, techniques, agents, methodologies, models, or approaches with potential clinical impact. They are expected to break new ground or extend prior discoveries in new directions or applications. Applicants are expected to propose research for which there is likely to be minimal or no preliminary data.

National Institutes of Health · Amount varies

This Notice of Funding Opportunity (NOFO) solicits applications to develop web-accessible data archives to capture, store, and curate data related to BRAIN Initiative activities. The data archives will work with the research community to incorporate tools that allow users to analyze and visualize the data, but the creation of such tools is not part of this NOFO. The data archives will use appropriate standards to describe the data, but the creation of such standards is not part of this NOFO. A goal of this program is to advance research by creating a community resource data archive with appropriate standards and summary information that is broadly available and accessible to the research community for furthering research.

Substance Abuse and Mental Health Services Adminis · $0–$150K

The purpose of this program is to strengthen the capacity and sustainability of statewide mental health peer-run organizations.

Substance Abuse and Mental Health Services Adminis · $0–$1.9M

The purpose of this program is to create a Center of Excellence for Eating Disorders. The Center will provide national training and technical assistance (TTA) to healthcare providers on screening, brief intervention, and referral to treatment for eating disorders. The Center will also provide TTA to paraprofessionals and relevant non-clinical community service providers. The TTA is intended to identify and support individuals across the lifespan, including children and youth, with or at risk for eating disorders.

Centers for Disease Control - NCCDPHP · $0

Alzheimer's disease, the most common form of dementia, is a progressive condition. It begins with mild memory loss and may lead to the inability to communicate or respond to one's environment. Its prevalence is rising with the aging U.S. population. In 2021, it was the 5th leading cause of death for those 65 and older, with death rates continuing to climb.The CDC Alzheimer's Disease Program, through the National Healthy Brain Initiative (HBI) and funded partners, promotes brain health, addresses cognitive impairment, and supports caregivers using evidence-based approaches. This funding opportunity aligns with the HBI Road Map Series (including the State & Local Road Map 2023–2027 and the Road Map for Indian Country) and fulfills the aims of the Building Our Largest Dementia (BOLD) Infrastructure for Alzheimer"s Act (P.L. 115-406).Funding Structure: Component 1: National Healthy Brain Initiative: Fund at least two (2) organizations to develop & implement public health strategies guided by the HBI Road Map Series. Funded organizations will: Develop evidence-informed training for health care and public health professionals on ADRD and caregiving. Expand the availability & use of public health surveillance data, including adaptation & revision of the Behavioral Risk Factor Surveillance System (BRFSS) subjective cognitive decline & caregiver optional modules. Facilitate the coordination of recipients & national partners to address ADRD. Funding range: $2,500,000 to $3,000,000 per 12-month budget period. Component 2: BOLD Public Health Centers of Excellence: Fund at least two (2) Centers, each specializing in one of three topic-specific areas: dementia risk reduction, early detection and management of dementia, or dementia caregiving. Centers will: Support the needs of the BOLD public health program and other public health agencies. Identify, disseminate, and promote best practices. Translate promising research into practical tools and resources. Increase professional education and develop materials to address specific individual needs to improve health outcomes. Funding range: $750,000 to $1,000,000 per 12-month budget period. Component 3: ADRD Public Health Adoption Accelerator. Fund up to two (2) organizations to serve as public health strategy adaptation accelerator programs. This means using dissemination and implementation of science to spread and put into practice effective public health strategies, tools, and resources to tackle ADRD. Organizations will: Collaborate with CDC and other organizations to create a prioritized list of ADRD approaches & strategies. Use proven strategies to engage partners, health care organizations, and policymakers to enhance uptake and implementation, accelerating the impact of ADRD efforts. Provide technical assistance to Component 1 & 2 recipients. Funding range: $750,000 - $1,200,000 per 12-month budget period. Applicants may apply for multiple components, but must submit a separate application per component.

Centers for Disease Control - NCIRD · $0

The purpose of this Notice of Funding Opportunity (NOFO) is to grow a network of researchers that strengthens CDC"s use of influenza modeling and forecasting to provide situational awareness, inform influenza prevention and control efforts, advance the science of influenza forecasting and modeling, and enhance communication of related findings with key partners, including state, local, and non-governmental organizations. These efforts will inform strategies to mitigate influenza-related morbidity and mortality. This includes populations at higher risk of influenza or with lower uptake of or access to influenza prevention and control measures.

National Institutes of Health · Amount varies

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish a Pharmacokinetics Resource Laboratory (PK Laboratory) to support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratory will organize biospecimen collections and provide subsequent analyses of pharmacokinetic endpoints, drug-drug interactions, cytochrome P450 (CYP) interactions, pharmacodynamics, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratory is to advance the clinical development of NCI IND agents by providing a comprehensive understanding of pharmacokinetic behavior of these agents under study in ETCTN trials. The ETCTN PK Laboratory will engage physicians, clinical pharmacologists, nurses, and scientists who have appropriate expertise in pharmacokinetic studies for early drug development and translational research. This NOFO seeks U24 applications from multidisciplinary institutions/organizations to conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to IND applications in the NCI Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

Rural Utilities Service · $50K–$750K

Authorized by 7 U.S.C. 950aaa, the DLT Program provides financial assistance to enable and improve distance learning and telemedicine services in rural areas. DLT grant funds support the use of telecommunications-enabled information, audio and video equipment, and related advanced technologies by students, teachers, medical professionals, and rural residents. These grants are intended to increase rural access to education, training, and health care resources that are otherwise unavailable or limited in scope. The regulation for the DLT Program can be found at 7 CFR part 1734. All applicants should carefully review and prepare their applications according to instructions in the FY 2026 DLT Grant Program Application Guide (Application Guide) and program resources. This Application Guide will be made available here and on the program website at https://www.rd.usda.gov/programs-services/distance-learning-telemedicine-grants. Expenses incurred in developing applications will be at the applicant’s own risk.

National Institutes of Health · Amount varies

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network.

National Institutes of Health · Amount varies

This BRAIN Initiative Notice of Funding Opportunity (NOFO) is to support scaled reagent production and distribution facilities involving technologies to access brain cell types. Facilities for production and distribution of these reagents by a broad set of neuroscientists will be encouraged. This NOFO is part of the BRAIN Initiative Armamentarium for Brain Cell Access transformative project. Efforts will be supported to produce and distribute gene transfer, gene regulation, and genome engineering reagents for use in both genetically tractable and less tractable systems, including primates and human tissue, which are relevant for future translational efforts. Reagents to be produced and distributed are those designed and validated under other NOFOs from the Armamentarium transformative project.